

1. Record Nr.	UNINA9910956689703321
Titolo	Developing a national registry of pharmacologic and biologic clinical trials : workshop report / / Committee on Clinical Trial Registries, Board on Health Sciences Policy, Institute of Medicine of the National Academies
Pubbl/distr/stampa	Washington, D.C., : National Academies Press, c2006
ISBN	0-309-18054-6 1-280-50667-9 9786610506675 0-309-65577-3
Edizione	[1st ed.]
Descrizione fisica	1 online resource (124 p.)
Disciplina	615.5072
Soggetti	Clinical trials - United States Clinical medicine - Research
Lingua di pubblicazione	Inglese
Formato	Materiale a stampa
Livello bibliografico	Monografia
Note generali	Description based upon print version of record.
Nota di bibliografia	Includes bibliographical references (p. 47-48).
Nota di contenuto	""Front Matter""; ""Independent Report Reviewers ""; ""Foreword ""; ""Preface ""; ""Contents ""; ""List of Tables ""; ""1 Summary ""; ""2 The Need for Clinical Trial Registries ""; ""3 Current Registry Activities ""; ""4 Content of a Clinical Trial Registry ""; ""5 Implementation Issues ""; ""6 Conclusion and Next Steps ""; ""References ""; ""APPENDIXES""; ""A Participants and Invited Experts Between December 1, 2004, and June 27, 2005""; ""B Workshop Agenda, Speakers, Panelists, and Participants: June 27, 2005"" ""C Section 113 of the Food and Drug Administration Modernization Act of 1997 and Guidance for Industry: Information Programs on Clinical Trials for Serious or Life- Threatening Diseases and Conditions. U.S. Department of Health and Human Services."""D Published Journal Editorials""; ""E Joint Position on the Disclosure of Clinical Trial Information via Clinical Trial Registries and Databases""; ""F Illustrative Data Fields for the Results Summary (based on ICH E3 template)""; ""G Biographical Sketches of Committee Members""
Sommario/riassunto	To improve public confidence in clinical research, a number of public

and private groups have called for a publicly accessible, comprehensive, and transparent registry of relevant information on clinical trials for drugs and biologics. The public and various entities within the medical community (health care providers, researchers, medical journal editors, pharmaceutical companies, health insurers, and regulators) have different expectations and perceived needs regarding a public clinical trial registry. The IOM Committee on Clinical Trial Registries hosted a workshop on June 27, 2005, to obtain much-needed input from members of the public, public advocate groups, and the broader community of journal editors, pharmaceutical and biotech leaders, NIH, and the FDA. Participants discussed the data elements that have been at the core of debate and commented on issues of compliance and implementation of a national clinical trial registry. Developing a National Registry of Pharmacologic and Biologic Clinical Trials: Workshop Report includes discussions at the workshop centered on the following five concepts, and are described within this report: 1) Purpose, 2) Which Trials to Include, 3) Delayed Disclosure Mechanism, 4) Reporting Results of Completed Trials, and 5) Compliance.
